LBT-SA7 (IBT-V02): A Rationally Designed Toxoid Vaccine Poised to Overcome Decades of Failure in the Staphylococcus aureus Field

Executive Summary

The landscape of Staphylococcus aureus vaccine development is a veritable graveyard of promising candidates, marked by decades of high-profile and costly clinical failures. LBT-SA7, a multivalent toxoid vaccine originally developed by Integrated BioTherapeutics (IBT) as IBT-V02 and now advanced by LimmaTech Biologics, represents a significant paradigm shift in this challenging field. This report posits that LBT-SA7 is built upon a scientifically rational and strategically de-risked foundation that directly addresses the fundamental flaws of its predecessors. By targeting key secreted toxins rather than bacterial surface antigens, the vaccine is engineered to neutralize the pathogen’s primary virulence and immune-evasion mechanisms, an approach strongly supported by extensive preclinical data and a growing understanding of S. aureus immunopathology.

The core innovation of LBT-SA7 lies in its mechanism. Historical attempts to develop an S. aureus vaccine have focused on generating opsonizing antibodies against surface antigens, a strategy that has not only failed to confer protection but has, in some cases, been associated with deleterious immune responses and increased mortality in vaccinated individuals who subsequently became infected.[1] LBT-SA7 circumvents this issue by targeting a cocktail of six rationally designed, detoxified proteins (toxoids) that neutralize the pathogen’s pore-forming toxins and superantigens.[5] This approach is designed to disarm the bacterium, protecting host tissues and preserving the integrity of the immune system, thereby allowing for effective clearance.

This novel strategy is underpinned by a robust preclinical evidence package that is unparalleled in the field. The vaccine has demonstrated remarkable efficacy in eight different animal models, including both mice and rabbits, where it generated potent neutralizing antibody responses.[1] Critically, these studies have shown that vaccination protects against both primary and recurrent infections, and that this protection is superior to the immunity conferred by natural infection alone—a pivotal finding that suggests the vaccine can overcome the inadequate immune memory that plagues human hosts.[7]

The program's strategic execution has been equally impressive. Its development has been substantially advanced through significant non-dilutive funding from a consortium of prestigious global health organizations, including CARB-X, the National Institute of Allergy and Infectious Diseases (NIAID), and the Novo Holdings REPAIR Impact Fund.[10] This external validation not only underscores the scientific merit of the approach but has also de-risked the program financially for its current developer, LimmaTech Biologics. Further bolstering its prospects, the U.S. Food and Drug Administration (FDA) has granted LBT-SA7 Fast Track designation, acknowledging the serious unmet medical need for an

S. aureus vaccine and providing a framework for an expedited development and review process.[15]

Looking forward, the program is at a critical inflection point. The ongoing Phase 1 clinical trial (NCT06719219) is designed to assess the vaccine's safety and immunogenicity in healthy human volunteers, with initial results anticipated in the second half of 2025.[19] Positive data from this study, demonstrating a favorable safety profile and the induction of potent toxin-neutralizing antibodies, would provide the first human validation of the toxoid-based strategy. Such an outcome would represent a monumental step forward in the fight against antimicrobial resistance and position LBT-SA7 as a leading, and potentially first-in-class, vaccine candidate in a field of immense unmet need.

The Staphylococcus aureus Vaccine Conundrum: A History of High-Profile Failures

The quest for a vaccine against Staphylococcus aureus is one of modern medicine's most urgent and frustrating challenges. This bacterium represents a profound threat to global public health, causing a wide spectrum of diseases from common skin and soft tissue infections (SSTIs) to life-threatening invasive conditions like bacteremia, pneumonia, and endocarditis.[7] The rise of methicillin-resistant

S. aureus (MRSA) has rendered many traditional antibiotic treatments ineffective, making S. aureus a leading cause of antimicrobial resistance (AMR)-related deaths and prompting the World Health Organization (WHO) to designate it a "high priority" pathogen.[10] The staggering morbidity, mortality, and economic burden associated with these infections underscore the critical need for a preventative vaccine.[2] Yet, despite decades of research and billions of dollars in investment, the field is littered with the wreckage of failed clinical trials.

The Prevailing Dogma and Its Failure

For years, the dominant paradigm in S. aureus vaccine development was based on a classical immunological principle: inducing high titers of opsonophagocytic antibodies against antigens expressed on the bacterial surface.[2] The theory was that these antibodies would coat the bacteria, marking them for destruction by the host's phagocytic immune cells, such as neutrophils and macrophages. This approach showed initial promise in preclinical animal models, which consistently demonstrated protection.[2] However, this success in animals has universally failed to translate to humans.[2] A review of the most prominent clinical failures reveals a consistent pattern of disappointment and, in some cases, alarming safety signals that have forced a fundamental re-evaluation of the entire strategy.

Case Study 1: Merck's V710 (IsdB) Vaccine

Merck's V710 vaccine was a single-antigen candidate based on the iron surface determinant B (IsdB), a protein highly conserved across S. aureus isolates and involved in iron acquisition, making it a seemingly ideal target.[27] Early Phase I studies in healthy adults showed that the vaccine was immunogenic and well-tolerated.[27]

This initial promise led to a large Phase IIb/III trial (NCT00518687) in patients undergoing cardiothoracic surgery, a population at high risk for postoperative S. aureus infections.[28] The trial was terminated in 2011 after an independent Data Monitoring Committee (DMC) review found that the vaccine was unlikely to meet its primary efficacy endpoint.[29] The failure was not merely one of futility; a subsequent post-hoc analysis uncovered a deeply troubling safety signal. Among patients who developed a postoperative

S. aureus infection, those who had received the V710 vaccine had a significantly higher mortality rate (23.0%) compared to those who received a placebo (4.2%).[3]

Further investigation to understand this disastrous outcome revealed a potential immunological basis for the harm. Mortality was starkly correlated with patients' pre-vaccination cytokine levels. All 12 V710 recipients who had undetectable serum levels of Interleukin-2 (IL-2) prior to vaccination and surgery died after their postoperative S. aureus infection, compared to only one of 13 similar patients in the placebo group.[3] A similar correlation was found for Interleukin-17a (IL-17a). This suggests that in individuals with a specific immune predisposition (low Th1/Th17 potential), the vaccine-induced antibody response against IsdB was not only non-protective but potentially harmful, possibly leading to an aberrant and fatal immune response upon subsequent infection.[3] The V710 trial stands as a stark warning about the potential for vaccine-induced disease enhancement with

S. aureus.

Case Study 2: Pfizer's SA4Ag (PF-06290510) Vaccine

Learning from the failures of single-antigen approaches, Pfizer developed SA4Ag, a multi-antigen vaccine targeting four distinct surface components: capsular polysaccharides types 5 and 8 (CP5, CP8), clumping factor A (ClfA), and a recombinant surface protein (P305A).[31] This four-component vaccine was granted Fast Track designation by the FDA and advanced into a large Phase 2b study known as STRIVE (NCT02388165), which began in 2015.[32] The trial aimed to evaluate the vaccine's efficacy in preventing postoperative invasive

S. aureus infections in adults undergoing elective spinal fusion surgery.[32]

Despite the more complex design, the outcome was the same. In late 2018, Pfizer announced that the STRIVE trial was being discontinued for futility.[34] An interim analysis by the DMC concluded that there was a low statistical probability of the study meeting its primary efficacy objective.[34] Unlike the V710 trial, the DMC noted that the SA4Ag vaccine had been safe and well-tolerated.[34] However, the lack of efficacy, despite inducing an antibody response, was another major blow to the surface-antigen hypothesis and led Pfizer to halt the program.[35]

Case Study 3: GSK's Candidate (GSK3878858A)

GlaxoSmithKline also pursued a multi-antigen strategy with its candidate, GSK3878858A, which contained five S. aureus antigens (Sa-5Ag) and was tested with and without an adjuvant.[38] A Phase I/II trial (NCT04420221) was initiated in 2020 to assess the vaccine in both healthy adults and in adults with a recent history of recurrent SSTIs.[38] However, in its 2022 year-end report, GSK quietly disclosed that the program was being discontinued following a futility analysis, adding another casualty to the list of failed surface-antigen-based vaccines.[36]

The "Original Antigenic Sin" of Staphylococcus aureus

The repeated and consistent failure of vaccines that performed well in animal models points to a fundamental disconnect between the preclinical models and human immunology. Recent research, particularly from a group at UC San Diego, offers a compelling explanation for this discrepancy, a concept that can be likened to "original antigenic sin".[37]

The reasoning proceeds as follows:

1. S. aureus is a human pathobiont, meaning it colonizes a significant portion of the human population from infancy without causing disease.[37] Laboratory mice, in contrast, are immunologically naive to S. aureus.
2. This lifelong colonization in humans allows the bacterium to "educate" or "trick" the host immune system. It appears to induce a primary immune response that is dominated by non-protective antibodies directed against its most abundant surface antigens.[42]
3. When a person is later vaccinated with a formulation based on these same dominant surface antigens (like IsdB or ClfA), the principle of immunological memory dictates that the immune system will preferentially recall and expand this pre-existing, non-protective antibody response.
4. This explains why the vaccines work "beautifully" in naive mice but fail in humans, who have already been immunologically "imprinted" by the bacterium to mount an ineffective response.[37]

This hypothesis elegantly explains the failures of Merck, Pfizer, and GSK not as isolated incidents, but as the predictable outcomes of a fundamentally flawed strategy. It implies that any vaccine targeting the same dominant surface antigens that the bacterium uses to establish colonization is likely doomed to fail in a human population that is not immunologically naive. This realization creates the central scientific rationale for the IBT-V02/LBT-SA7 approach. By targeting secreted toxins—which are virulence factors responsible for disease, not colonization factors—the vaccine aims to induce a type of protective immunity that the host does not naturally develop, thereby bypassing this "original antigenic sin."

Table 1: Comparative Analysis of Failed S. aureus Vaccine Candidates
Candidate Name (Developer)	Antigens	Mechanism of Action	Target Population	Phase of Failure	Reason for Failure
V710 (Merck)	Iron surface determinant B (IsdB)	Opsonophagocytic killing	Cardiothoracic surgery patients	Phase IIb/III	Safety (Increased mortality in vaccinees with subsequent infection) & Futility 3
SA4Ag (Pfizer)	CP5, CP8, ClfA, P305A	Opsonophagocytic killing	Spinal fusion surgery patients	Phase 2b	Futility (No efficacy despite being safe) 34
GSK3878858A (GSK)	5 S. aureus antigens (Sa-5Ag)	Opsonophagocytic killing	Healthy adults & patients with recurrent SSTI	Phase I/II	Futility 36
StaphVAX (Nabi)	CP5, CP8 conjugated to P. aeruginosa exotoxin A	Opsonophagocytic killing	Hemodialysis patients	Phase III	Futility (Failed to show efficacy in second Phase III trial) 28

LBT-SA7: A Paradigm Shift in Vaccine Design and Composition

In stark contrast to the failed strategies of the past, LBT-SA7 is built on a different immunological foundation. The central hypothesis is that preventing S. aureus disease does not require sterile immunity (i.e., complete bacterial clearance), but rather the neutralization of the key toxins the bacterium uses to destroy host tissue, evade immune cells, and cause disease.[1] By disarming the pathogen's primary weapons, the vaccine aims to provide clinical protection, allowing the host's own immune system to effectively control and clear the infection.

Rational, Structure-Based Design

A critical feature of the LBT-SA7 program is its use of rational, structure-based design. The components are not crude or chemically inactivated toxins; they are recombinant proteins that have been precisely engineered with specific amino acid mutations. These mutations were designed based on the toxins' crystal structures to eliminate their toxicity while preserving the key three-dimensional epitopes necessary to elicit a robust and neutralizing antibody response.[5] This sophisticated protein engineering approach is intended to maximize immunogenicity and safety.

Detailed Vaccine Composition

LBT-SA7 is a multivalent vaccine that comprises five distinct, purified recombinant protein components, which collectively target six key S. aureus toxins. The components are blended at equal weight ratios and formulated with an adjuvant.[5]

• Alpha hemolysin (Hla) Toxoid: Hla is a potent pore-forming toxin that lyses a wide variety of host cells. The vaccine component contains two mutations, H35L and H48L, in the N-terminal domain. These mutations prevent the individual Hla monomers from assembling into the heptameric pore structure, thereby rendering the protein completely non-toxic.[5]
• Panton-Valentine leukocidin (PVL) Toxoid: PVL is a bicomponent toxin strongly associated with virulent community-acquired MRSA strains. The vaccine includes mutated versions of both of its subunits:
• LukS_mut9: The 'S' component contains three mutations (T28F, K97A, S209A).
• LukF_mut1: The 'F' component contains a single mutation (K102A). These toxoids have been shown to be fully attenuated and non-toxic.5
• Leukocidin AB (LukAB) Toxoid: LukAB is another bicomponent leukotoxin that is present in virtually all known S. aureus clinical isolates and is highly effective at killing human phagocytes.[26] The vaccine utilizes a dimeric toxoid, LukABmut50, which contains attenuating mutations in both subunits: D39A in LukA and R23E in LukB. These changes abrogate the protein's ability to form pores in target cell membranes.[5]
• Superantigen Fusion Protein (TBA225): To address the immune-dysregulating effects of superantigens, the vaccine includes a single, engineered fusion protein that incorporates toxoids of three of the most important superantigens. The individual toxoids are joined by a flexible 3x(GGGGS) linker in the order of TSST-1, SEB, and SEA.[5] The mutations are designed to disrupt the binding site for the Major Histocompatibility Complex (MHC) Class II molecules on antigen-presenting cells, which prevents the massive, non-specific T-cell activation that defines superantigenicity. The specific mutations are:
• Toxic Shock Syndrome Toxin-1 (TSST-1): L30R, D27A, I46A
• Staphylococcal Enterotoxin B (SEB): L45R, Y89A, Y94A
• Staphylococcal Enterotoxin A (SEA): L48R, D70R, Y92A, H225A.[5]

Formulation and Adjuvant

The five purified protein components are expressed in E. coli, purified via multi-step chromatography, and then blended at equal weight ratios.[5] The final vaccine product is formulated with

Alhydrogel®, a brand of aluminum hydroxide (Al(OH)3​), which serves as an adjuvant to enhance the immune response.[5] Formulation optimization studies demonstrated that a minimum of a three-fold excess of Alhydrogel® relative to the protein content was necessary to ensure complete adsorption of all five components, a critical step for stability and proper immune presentation.[5]

A Platform for Future Multivalent Vaccines

The development of LBT-SA7 is more than just the creation of a single product; it is the validation of a sophisticated technology platform. The ability to express five distinct, complex recombinant proteins (including a tri-toxin fusion protein), purify them to a high degree, and then formulate them into a stable, single-dose vaccine is a significant manufacturing and bioengineering achievement.[5] This demonstrates a robust capability in rational protein design, expression, purification, and multi-component formulation. This validated platform could be readily adapted to address other complex pathogens that rely on a diverse arsenal of secreted toxins for their virulence, such as

Clostridium difficile or other Gram-positive bacteria. This underlying platform technology represents a significant, and often overlooked, source of value for LimmaTech Biologics, extending far beyond the commercial potential of the S. aureus vaccine alone.

Table 2: Detailed Composition of the LBT-SA7 Multivalent Toxoid Vaccine
Component Name	Target Toxin(s)	Specific Mutations	Rationale for Mutation
Hla Toxoid	Alpha hemolysin (Hla)	H35L, H48L	Prevents heptamerization and pore formation, eliminating cytotoxicity.5
PVL Toxoid	Panton-Valentine leukocidin (LukS/LukF)	LukS: T28F/K97A/S209ALukF: K102A	Fully attenuates toxicity of both subunits, even in combination with wild-type partners.5
LukAB Toxoid (LukABmut50)	Leukocidin AB (LukA/LukB)	LukA: D39ALukB: R23E	Prevents pore formation in the plasma membrane of target immune cells.5
Superantigen Fusion (TBA225)	TSST-1, SEB, SEA	TSST-1: L30R/D27A/I46ASEB: L45R/Y89A/Y94ASEA: L48R/D70R/Y92A/H225A	Disrupts binding to MHC Class II, eliminating superantigenicity and preventing polyclonal T-cell activation.5

Immunological Mechanism: Neutralizing Virulence to Enable Host Defense

The mechanism of action for LBT-SA7 is fundamentally different from previous vaccine attempts. Instead of priming the immune system to attack the bacteria directly, it aims to create a "permissive environment" where the host's own natural defenses can function without being subverted by the pathogen's powerful arsenal of toxins. This is achieved through a sophisticated, multi-pronged immunological strategy.

Shifting the Immune Target from Bacterium to Toxin

The primary and most direct mechanism is the induction of high-titer, polyclonal neutralizing antibodies against the six toxins included in the vaccine formulation.[6] When a vaccinated individual is subsequently exposed to

S. aureus, these circulating antibodies are intended to immediately bind to and neutralize the secreted toxins before they can damage host tissues or incapacitate immune cells. This shifts the focus of the immune response from the bacterial cell surface—a target that has proven problematic—to the soluble virulence factors that are the primary drivers of disease pathology.

Protecting the Immune System from Itself

A key component of S. aureus pathogenesis, particularly in severe systemic disease, is the activity of superantigens like TSST-1, SEA, and SEB. These molecules bypass normal antigen presentation and directly cross-link T-cell receptors with MHC Class II molecules on antigen-presenting cells. This triggers a massive, non-specific activation of a large fraction of the body's T-cells, leading to a "cytokine storm" that can cause toxic shock, multi-organ failure, and death.[5] This overwhelming response is not only damaging but also counterproductive, as it can lead to the widespread death (apoptosis) or functional inactivation (anergy) of T-cells, crippling the adaptive immune response needed to clear the infection.[6] By inducing neutralizing antibodies against these superantigens, the TBA225 component of the vaccine is designed to prevent this catastrophic immune dysregulation, preserving the integrity and functionality of the host's T-cell compartment.

Protecting Tissues and Innate Immunity

Simultaneously, the vaccine targets the pore-forming cytotoxins Hla, PVL, and LukAB. These toxins are the bacterium's frontline weapons, used to disrupt epithelial and mucosal barriers and to kill the host's first-line immune defenders, particularly neutrophils and macrophages.[5] By neutralizing these toxins, the vaccine is expected to protect the physical integrity of tissues like the skin and lungs and, critically, to shield the innate immune cells that are essential for phagocytosing and clearing the bacteria. This allows the innate immune system to function effectively at the site of infection.

Priming a Localized T-Cell Response

While the primary protective mechanism is believed to be antibody-mediated, emerging evidence suggests a role for cellular immunity as well. A 2024 study investigated the T-cell response to IBT-V02 vaccination in a mouse model of skin infection.[9] Using an IL-17A/F dual fluorescent reporter mouse, researchers discovered that vaccinated mice exhibited a marked increase in IL-17A and IL-17F expression in the skin even before being challenged with the bacteria. This response was correlated with an increase in IL-17-producing CD8+ and γδ+ T-cells, particularly within the epidermal compartment. The localization of these cells in the epidermis is characteristic of tissue-resident memory T-cells (Trm), a specialized subset of T-cells that provide rapid, localized protection at barrier sites. The study found that both IL-17A/F and Trm cells were involved in the protection elicited by the vaccine.[9]

This finding suggests a more sophisticated mechanism than simple antibody neutralization. The vaccine may not only provide a systemic shield of neutralizing antibodies but may also establish a pre-positioned garrison of memory T-cells in the skin, ready to mount a rapid and effective local response upon bacterial entry. By neutralizing the toxins that would otherwise kill or paralyze immune cells, the vaccine creates a permissive environment where both the innate phagocytes and these primed Trm cells can effectively combat the pathogen. This dual mechanism—a systemic antibody shield combined with a localized cellular response—represents a powerful and multifaceted defense that is far more robust than that induced by natural infection or by previous vaccine candidates.

The Preclinical Evidence Dossier: A Foundation of Robust Efficacy

A cornerstone of the LBT-SA7 program is the depth and breadth of its preclinical data package, which stands in stark contrast to the more limited animal studies that supported previously failed vaccine candidates. The vaccine has been rigorously tested across multiple species and infection models, providing a strong foundation of evidence for its potential efficacy in humans.

Breadth of Models and Immunogenicity

The vaccine's efficacy has been demonstrated in at least eight different animal models, utilizing both mice and rabbits, which adds to the robustness of the findings.[1] In these models, immunization with the adjuvanted, five-component vaccine consistently generates high titers of antigen-specific IgG antibodies.[7] More importantly, the induced antibodies demonstrate potent toxin-neutralizing activity against all the wild-type toxins targeted by the vaccine, including Hla, PVL, LukAB, SEA, SEB, and TSST-1.[7]

A particularly compelling finding is the vaccine's ability to induce cross-neutralizing antibodies. The immune response generated by the toxoids is not limited to the specific antigens in the vaccine. Data suggests the antibodies can neutralize a broader family of related staphylococcal toxins, providing coverage against an estimated 12 to 15 different toxins.[7] This broad spectrum of activity is a significant advantage, as it suggests the vaccine could be effective against a wide diversity of clinical

S. aureus strains, which can vary in their specific toxin expression profiles.

Protective Efficacy in Challenge Models

The preclinical studies have demonstrated clear protective efficacy against clinically relevant bacterial challenges.

• Primary Infection: In models of acute skin infection, active immunization with LBT-SA7 protected animals from disease caused by several diverse and clinically important S. aureus strains, including representative clones of USA100, USA300 (a common cause of community-acquired MRSA), and USA1000.[7]
• Recurrent Infection: A pivotal set of experiments addressed the challenge of recurrent infections, a major clinical problem. In these studies, mice that were vaccinated with LBT-SA7 were protected from a secondary (recurrent) infection. In contrast, mice that experienced a primary infection but were not vaccinated were not protected from a subsequent challenge.[7] This is a crucial finding, as it directly supports the central hypothesis that natural infection with S. aureus induces a suboptimal or non-protective immune memory, whereas the toxoid vaccine induces a superior and truly protective response.
• Passive Transfer of Immunity: To confirm the central role of antibodies in protection, serum from vaccinated animals was transferred to naive animals. These recipient animals were then protected from a subsequent bacterial challenge, demonstrating that the vaccine-induced antibodies are the primary mediator of the protective effect.[7]

Formulation Stability

Recognizing the global nature of the S. aureus threat, the development program also included the creation of a freeze-dried (lyophilized) formulation of the vaccine. This is critical for deployment in regions that may lack reliable cold-chain infrastructure. Preclinical studies confirmed that this lyophilized version of the vaccine retains its full in vivo efficacy, demonstrating its suitability for global health applications.[10]

Overcoming a Key Hurdle for Human Translation

Perhaps the most significant aspect of the LBT-SA7 preclinical package is how it directly confronts the likely reason for past clinical failures. As established, a leading hypothesis for the failure of vaccines like Merck's V710 and Pfizer's SA4Ag is that they did not work in immunologically experienced humans, even though they worked in naive mice.[37] The LBT-SA7 development program is unique in that it has specifically tested this hypothesis. The recurrent infection models show that the vaccine-induced immunity is superior to natural immunity.[7] Even more directly, a 2024 study demonstrated that the vaccine remained efficacious even in mice that had been

previously exposed to S. aureus in the skin, thereby mimicking the immunologically "imprinted" state of the human population.[9] This is a pivotal experiment that no other failed vaccine program appears to have conducted. By showing that the vaccine can overcome the non-protective immunity induced by prior exposure, this finding provides the strongest evidence to date that LBT-SA7 may succeed where others have failed. This significantly de-risks the transition to human trials and is a crucial differentiator for the program.

The Path to Human Validation: The LBT-SA7 Phase 1 Clinical Program

With a strong foundation of preclinical evidence and a compelling scientific rationale, the LBT-SA7 program has advanced into the most critical phase of its development: human clinical trials. The ongoing Phase 1 study represents the first test of the toxoid vaccine hypothesis in humans and is a pivotal, value-driving catalyst for LimmaTech Biologics and its partners.

Trial Design and Key Parameters

The first-in-human trial is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study being conducted in the United States.[16] As of February 2025, the trial is actively recruiting, and the first participants have been vaccinated.[19]

The study is designed to enroll 130 healthy adult volunteers between the ages of 18 and 50.[19] Participants are randomized to receive one of three dose levels of LBT-SA7 (low, medium, or high) or a placebo (saline).[45] The dosing schedule involves either one or two intramuscular injections, with the two-dose regimens being administered one month apart.[45]

The primary objectives of the trial are to rigorously evaluate the safety and immunogenicity of the LBT-SA7 vaccine.[19]

• Safety: This will be assessed through the collection of solicited local and systemic adverse events via participant diaries, unsolicited adverse events, and monitoring of laboratory safety parameters.[45]
• Immunogenicity: The key endpoint is the measurement of the immune response generated by the vaccine. This will involve quantifying the levels of antigen-specific antibodies in the blood (e.g., via ELISA) and, critically, assessing the functional, toxin-neutralizing capacity of the antibodies in the participants' sera.[16]

According to the trial sponsors, initial results from this study are anticipated in the second half of 2025.[19]

A Well-Designed Trial to Answer the Key Questions

The design of the NCT06719219 trial is robust and well-suited to address the primary questions for a novel vaccine at this stage. The randomized, placebo-controlled, dose-escalation design is the gold standard for establishing a safe and immunologically active dose range in a first-in-human study.[45]

Crucially, the trial's immunogenicity endpoints are not merely the presence of antibodies, but their functional ability to neutralize the target toxins.[16] This directly links the human trial back to the preclinical models, where toxin neutralization was the key correlate of protection. Therefore, the trial is designed to answer the most important question: can LBT-SA7 safely induce a functionally relevant immune response in humans?

A positive outcome from this trial would be a monumental achievement. If LBT-SA7 is shown to be safe and capable of generating potent toxin-neutralizing antibody titers in humans, it would provide the first concrete evidence that the toxoid-based strategy is viable and can be successfully translated from animals to humans. This would be a major de-risking event, dramatically increasing the asset's value and attracting significant interest from potential partners and investors for the larger and more expensive Phase 2 and 3 trials required for licensure. The data readout in the latter half of 2025 is thus the single most important near-term event for the LBT-SA7 program and a highly anticipated moment for the entire AMR field.

Table 3: Design and Key Parameters of the NCT06719219 Phase 1 Trial
Parameter	Detail
NCT ID	NCT06719219 20
Title	A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus 50
Status	Recruiting 53
Phase	Phase 1 19
Sponsor	LimmaTech Biologics AG 20
Design	Randomized, double-blind, placebo-controlled, dose-escalation 19
Population	Healthy Adults 20
Number of Participants	130 19
Interventions	Three dose levels of LBT-SA7 (adjuvanted with Alhydrogel®) vs. Placebo (saline). One or two intramuscular injections. 45
Primary Endpoints	Safety (incidence of adverse events) and Immunogenicity (toxin-neutralizing antibody titers) 19
Key Secondary Endpoints	Antigen-specific antibody concentrations (ELISA) 52
Estimated Primary Completion Date	May 31, 2026 50
Anticipated Initial Results	Second half of 2025 19

Corporate Strategy and Regulatory Acceleration

The journey of LBT-SA7 from a laboratory concept to a clinical-stage asset is a case study in modern, capital-efficient biotechnology strategy. The program has been skillfully navigated through its high-risk early stages with non-dilutive funding and has now been placed in the hands of a focused clinical development company, all while benefiting from a streamlined regulatory pathway.

The Development Pathway: From IBT to LimmaTech

The vaccine, originally designated IBT-V02, was discovered and advanced through its entire preclinical development by Integrated BioTherapeutics (IBT), a Rockville, Maryland-based biotech company founded in 2005.[43] The vaccine program was later housed within IBT's spin-off, IBT Vaccines, which was subsequently renamed AbVacc, Inc. in January 2023.[11]

In a key strategic move announced in December 2023, the Swiss-based company LimmaTech Biologics AG acquired an exclusive license to advance the clinical development of the vaccine, now renamed LBT-SA7.[14] This agreement gives LimmaTech, a company with deep expertise in vaccine development, control over the crucial clinical stages. The deal structure is also strategically sound, granting LimmaTech an exclusive option to acquire full worldwide rights to the program following the Phase 1 data readout, allowing the company to make a fully informed investment decision at the next major value inflection point.[14]

The Power of Non-Dilutive Funding

A defining feature of the LBT-SA7 story is its reliance on non-dilutive funding to navigate the "valley of death" of early-stage drug development. Instead of relying solely on venture capital, which would have diluted ownership and placed immense pressure for a premature exit, IBT/AbVacc secured substantial financial and in-kind support from a consortium of prestigious global health organizations. This strategy not only preserved capital but also provided powerful external validation of the program's scientific merit. Key funding partners include:

• CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator): This global non-profit partnership, led by Boston University, has been a steadfast supporter. CARB-X provided an initial award in 2017 of up to $8.5 million, a subsequent award of $1.6 million in 2019 to develop a thermostable lyophilized formulation, and a further award of $6.5 million in 2025 to advance the program into Phase 1 clinical trials.[10]
• National Institute of Allergy and Infectious Diseases (NIAID): Part of the U.S. National Institutes of Health (NIH), NIAID has provided significant support through multiple research grants (including R43AI085665 and R01AI111205) and critical in-kind support in the form of access to its suite of preclinical development services.[1]
• Novo Holdings REPAIR Impact Fund: This fund, focused on combating AMR, made a strategic investment in IBT Vaccines (now AbVacc) in 2019/2020, providing crucial private-sector validation and capital to bolster the vaccine's preclinical development.[1]
• U.S. Department of Defense (DoD): The DoD has also been cited as a source of funding, highlighting the importance of an S. aureus vaccine for military populations who are at high risk of traumatic wound infections.[43]

Regulatory Acceleration: FDA Fast Track Designation

In December 2024, the FDA granted Fast Track designation to LBT-SA7, a significant regulatory milestone.[15] This designation is reserved for drugs and vaccines that are intended to treat serious conditions and that demonstrate the potential to address an unmet medical need.[18]

The granting of Fast Track status provides several tangible benefits that can accelerate the path to market. These include the opportunity for more frequent meetings and written communication with the FDA to discuss the clinical development plan, ensuring alignment on trial design and data requirements. It also confers eligibility for Accelerated Approval and Priority Review, and perhaps most importantly, allows for a "Rolling Review" of the eventual Biologics License Application (BLA). This means LimmaTech can submit completed sections of its application for review by the FDA on an ongoing basis, rather than waiting until the entire application is complete, a process that can significantly shorten the overall review timeline.[18]

The strategic journey of LBT-SA7 exemplifies a highly effective model for developing high-risk, high-reward therapeutics. By leveraging public and non-profit funding for the riskiest discovery and preclinical phases, the program was able to mature and generate a compelling data package without the typical pressures of venture-backed startups. LimmaTech was then able to license a de-risked, clinical-ready asset, positioning it to focus its resources on execution. This capital-efficient pathway, combined with the regulatory advantages of Fast Track designation, makes LBT-SA7 a uniquely compelling asset from both a scientific and a business perspective.

Conclusive Analysis and Strategic Outlook

The LBT-SA7 program represents a beacon of hope in the challenging field of Staphylococcus aureus vaccine development. Its unique approach, robust preclinical validation, and strategic execution position it as a leading candidate to finally deliver a much-needed preventative tool against this formidable pathogen. However, the path forward is not without significant risks inherent to vaccine development.

Strengths (The Bull Case)

• Compelling Scientific Rationale: The toxoid-neutralizing strategy is the program's greatest strength. It is a scientifically sound approach that directly addresses the likely immunological reasons—the "original antigenic sin"—that caused decades of surface antigen-based vaccines to fail in human trials.
• Extensive and Positive Preclinical Data: The vaccine is supported by an unusually strong preclinical data package, demonstrating efficacy in eight animal models and, most critically, in a recurrent infection model that mimics the immunologically experienced human state. The induction of broad, cross-neutralizing antibodies is another significant advantage.
• Significant External Validation: The program has been repeatedly vetted and funded by some of the world's most sophisticated global health and anti-AMR organizations, including CARB-X, NIAID, and the Novo Holdings REPAIR Impact Fund. This serves as a powerful, independent endorsement of the science and strategy.
• Regulatory Advantage: The FDA's granting of Fast Track designation provides a clear and potentially accelerated regulatory path to market, acknowledging the program's potential to address a serious unmet medical need.
• Strong Commercial Partner: The licensing of the asset to LimmaTech Biologics places it in the hands of a company with dedicated expertise in vaccine development and clinical execution, increasing the probability of success in the crucial next stages.

Risks and Mitigation (The Bear Case)

• The "Graveyard" of S. aureus Vaccines: The primary risk is the daunting history of the field. No S. aureus vaccine has ever succeeded in a pivotal human trial, and the risk of unexpected outcomes in human immunology remains. The key mitigating factor is the preclinical data from the prior-exposure model, which was specifically designed to address this translational gap.
• Manufacturing Complexity (CMC): The vaccine is a complex biological product, consisting of five distinct recombinant proteins that must be manufactured to high standards, blended in precise ratios, and formulated with an adjuvant. While this has been achieved at the preclinical scale, scaling this process up to commercial levels while maintaining consistency and quality will be a significant technical challenge.
• Competitive Landscape: While LBT-SA7 appears to be the leading candidate with a toxoid-based approach, the field is not empty. There are over two dozen other S. aureus vaccine candidates in development, though most are in early preclinical stages.[23] The most advanced candidates from major pharmaceutical companies (Pfizer, Merck, GSK) have all been discontinued, clearing the competitive field to some extent, but new entrants could emerge.

Future Milestones and Valuation Inflection Points

The value of the LBT-SA7 program will be driven by the successful achievement of key near- and mid-term milestones:

1. H2 2025: Phase 1 Data Readout: This is the single most important upcoming catalyst. Positive safety and immunogenicity data, demonstrating the induction of potent toxin-neutralizing antibodies in humans, will be a major de-risking event and will likely trigger a significant increase in the asset's valuation.
2. Post-Phase 1: Following a successful Phase 1 readout, LimmaTech will likely exercise its option to acquire full worldwide rights to the program. This may be followed by a significant financing event or a partnership with a larger pharmaceutical company to fund the more extensive and costly later-stage trials.
3. Phase 2/3 Initiation: The next logical step would be the initiation of a Phase 2 or Phase 2/3 adaptive design trial in a relevant at-risk population. Potential target populations could include patients with a history of recurrent SSTIs or patients scheduled for high-risk elective surgeries, such as spinal fusion or joint replacement.

Final Recommendation

LBT-SA7 stands out as one of the most promising and strategically sound vaccine candidates in the entire antimicrobial resistance pipeline. Its development is built on a strong, logical foundation that thoughtfully incorporates the hard-learned lessons from the failures of the past. The combination of a novel mechanism that circumvents prior obstacles, an exceptionally robust preclinical data package, significant non-dilutive funding from premier organizations, and a clear, accelerated regulatory path makes LBT-SA7 a high-potential asset.

While the inherent risks of vaccine development can never be fully discounted, LBT-SA7 is uniquely positioned to potentially become the first-in-class preventative therapy for Staphylococcus aureus infections. A successful outcome would be a landmark achievement for global public health and would represent a commercial opportunity of immense scale. The upcoming Phase 1 results will be a pivotal moment, and a positive readout would validate this novel approach and signal a potential turning point in the long and arduous fight against this deadly pathogen.

Works cited

1. Pipeline - AbVacc, accessed June 17, 2025, https://abvacc.com/vaccine.html
2. Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms | FEMS Microbiology Reviews | Oxford Academic, accessed June 17, 2025, https://academic.oup.com/femsre/article/44/1/123/5679032
3. Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: An analysis of possible contributing host factors - PMC, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4514053/
4. Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/25483690/
5. IBT-V02: A Multicomponent Toxoid Vaccine Protects ... - Frontiers, accessed June 17, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.624310/full
6. IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7987673/
7. IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/33777005/
8. (PDF) IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/349507129_IBT-V02_A_Multicomponent_Toxoid_Vaccine_Protects_Against_Primary_and_Secondary_Skin_Infections_Caused_by_Staphylococcus_aureus
9. IBT-V02 vaccination elicits protection against recurrent Staphylococcus aureus​​​​​​​ skin infections - AAI Journals, accessed June 17, 2025, https://journals.aai.org/jimmunol/article/212/1_Supplement/0748_7624/268545/IBT-V02-vaccination-elicits-protection-against
10. $1.6 Million Dollars Awarded to Develop Staphylococcus Aureus Bacteria Vaccine, accessed June 17, 2025, https://www.vax-before-travel.com/ibt-v02-multivalent-s-aureus-vaccine-candidate-based-rationally-designed-toxoids
11. IBT Vaccines Receives $3.9 mil. to Advance Development of IBT-V02 Against MRSA - IBT, accessed June 17, 2025, https://ibtbioservices.com/ibt_news_publication/ibt-vaccines-receives-3-9-mil-to-advance-development-of-ibt-v02-against-mrsa/
12. CARB-X backs Integrated Biotherapeutics to accelerate the development of a novel toxoid-based vaccine to prevent drug-resistant MRSA infections, accessed June 17, 2025, https://carb-x.org/carb-x-news/carb-x-backs-integrated-biotherapeutics-to-accelerate-the-development-of-a-novel-toxoid-based-vaccine-to-prevent-drug-resistant-mrsa-infections/
13. CARB-X launches 2025 Funding Round targeting global infectious disease threats, accessed June 17, 2025, https://carb-x.org/carb-x-news/carb-x-launches-2025-funding-round-targeting-global-infectious-disease-threats/
14. LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc's Innovative Vaccine Candidate Against Staphylococcus aureus - Business Wire, accessed June 17, 2025, https://www.businesswire.com/news/home/20231219129237/en/LimmaTech-Biologics-Expands-Vaccine-Pipeline-by-Licensing-AbVaccs-Innovative-Vaccine-Candidate-Against-Staphylococcus-aureus
15. LBT-SA7 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 17, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/7d82dcf7f44b49faa649601bfc4ea2f1
16. LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus - Business Wire, accessed June 17, 2025, https://www.businesswire.com/news/home/20241219504299/en/LimmaTech-Awarded-FDA-Fast-Track-Designation-for-Vaccine-Candidate-Against-Staphylococcus-aureus
17. FDA Awards Fast Track Designation to Staphylococcus aureus Vaccine Candidate, accessed June 17, 2025, https://www.pharmacytimes.com/view/fda-awards-fast-track-designation-to-staphylococcus-aureus-vaccine-candidate
18. Fast Track | FDA, accessed June 17, 2025, https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
19. LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7 - BioSpace, accessed June 17, 2025, https://www.biospace.com/press-releases/limmatech-vaccinates-first-participants-in-phase-1-study-of-staphylococcus-aureus-vaccine-candidate-lbt-sa7
20. LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7 - Business Wire, accessed June 17, 2025, https://www.businesswire.com/news/home/20250217309427/en/LimmaTech-Vaccinates-First-Participants-in-Phase-1-Study-of-Staphylococcus-aureus-Vaccine-Candidate-LBT-SA7
21. Rational Design of Toxoid Vaccine Candidates for Staphylococcus aureus Leukocidin AB (LukAB) - MDPI, accessed June 17, 2025, https://www.mdpi.com/2072-6651/11/6/339
22. FDA fast-tracks Staph aureus vaccine | CIDRAP - University of Minnesota, accessed June 17, 2025, https://www.cidrap.umn.edu/antimicrobial-stewardship/fda-fast-tracks-staph-aureus-vaccine
23. Staphylococcus aureus - Vaccines for AMR, accessed June 17, 2025, https://vaccinesforamr.org/review-of-pathogens/pathogen-profiles/staphylococcus-aureus/
24. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Clinical Trials Featuring 25+ companies - BioSpace, accessed June 17, 2025, https://www.biospace.com/methicillin-resistant-staphylococcus-aureus-infection-pipeline-clinical-trials-featuring-25-companies
25. Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus | PNAS, accessed June 17, 2025, https://www.pnas.org/doi/10.1073/pnas.1424924112
26. Rational Design of Toxoid Vaccine Candidates for Staphylococcus aureus Leukocidin AB (LukAB) - PubMed, accessed June 17, 2025, https://pubmed.ncbi.nlm.nih.gov/31207937/
27. Safety and Immunogenicity of a Novel Staphylococcus aureus Vaccine: Results from the First Study of the Vaccine Dose Range in Humans - ASM Journals, accessed June 17, 2025, https://journals.asm.org/doi/10.1128/cvi.00356-10
28. The Candidate Antigens to Achieving an Effective Vaccine against Staphylococcus aureus, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8876328/
29. Staphylococcus aureus vaccine(Valneva SE) - Drug Targets, Indications, Patents - Synapse, accessed June 17, 2025, https://synapse.patsnap.com/drug/b8171219ca00486693436dc8fa50e71e
30. Merck & Co., Inc. and Intercell AG Announce Termination of Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 - BioSpace, accessed June 17, 2025, https://www.biospace.com/merck-and-co-inc-and-intercell-ag-announce-termination-of-phase-ii-iii-clinical-trial-of-investigational-staphylococcus-aureus-vaccine-v710
31. The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial - PMC, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10371312/
32. Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery, accessed June 17, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizer_begins_phase_2b_study_of_its_investigational_multi_antigen_staphylococcus_aureus_vaccine_in_adults_undergoing_elective_spinal_fusion_surgery
33. Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial | Clinical Infectious Diseases | Oxford Academic, accessed June 17, 2025, https://academic.oup.com/cid/article/77/2/312/7147455
34. Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis | Pfizer, accessed June 17, 2025, https://www.pfizer.com/news/press-release/press-release-detail/independent_data_monitoring_committee_recommends_discontinuation_of_the_phase_2b_strive_clinical_trial_of_staphylococcus_aureus_vaccine_following_planned_interim_analysis
35. Pfizer cans $500M staph vaccine hopeful after phase 2b trial failure | Fierce Pharma, accessed June 17, 2025, https://www.fiercepharma.com/vaccines/pfizer-s-s-aureus-vaccine-faces-uncertain-future-after-phase-2b-trial-failure
36. Ouch! Pfizer terminates S. aureus vaccine trial due futility (Part 3 of 3) - AMR.Solutions, accessed June 17, 2025, https://amr.solutions/2018/12/20/ouch-pfizer-terminates-s-aureus-vaccine-trial-due-futility/
37. The world needs a staph vaccine—new research could bring it a step closer, accessed June 17, 2025, https://id-ea.org/the-world-needs-a-staph-vaccine-new-research-could-bring-it-a-step-closer/
38. *STAPH AUREUS BIOCONJ-001 STG - Health Research Authority, accessed June 17, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/staph-aureus-bioconj-001-stg/
39. Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI) - ClinicalTrials.Veeva, accessed June 17, 2025, https://ctv.veeva.com/study/safety-immunogenicity-and-efficacy-of-gsk-s-aureus-candidate-vaccine-gsk3878858a-when-administer
40. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4514337/
41. GSK Culls Celiac, S. aureus Candidates on FDA Decision Day for CKD Drug - BioSpace, accessed June 17, 2025, https://www.biospace.com/gsk-culls-celiac-s-aureus-candidates-on-decision-day-for-ckd-drug
42. We Need a Staph Vaccine: Here's Why We Don't Have One - UC San Diego Today, accessed June 17, 2025, https://today.ucsd.edu/story/we-need-a-staph-vaccine-heres-why-we-dont-have-one
43. Integrated BioTherapeutics - PMC - PubMed Central, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6037449/
44. Full article: Integrated BioTherapeutics, accessed June 17, 2025, https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1440105
45. A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus., accessed June 17, 2025, https://www.trialstoday.org/trial/NCT06719219
46. Integrated Biotherapeutics Partners With CARB-X the First Toxoid Based Multivalent Vaccine for Methicillin-Resistant Staphylococcus Aureus - BioSpace, accessed June 17, 2025, https://www.biospace.com/integrated-biotherapeutics-inc-partners-with-carb-x-the-first-toxoid-based-multivalent-vaccine-for-methicillin-resistant-staphylococcus-aureus
47. IBTV-02 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 17, 2025, https://synapse.patsnap.com/drug/5e0f623b11c24a2f9a53590c32f9c468
48. LimmaTech: First patients vaccinated against Staphylococcus aureus – Swiss Biotech, accessed June 17, 2025, https://www.swissbiotech.org/listing/limmatech-vaccinates-first-participants-in-phase-1-study-of-staphylococcus-aureus-vaccine-candidate-lbt-sa7/
49. LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7 - Pipelinereview, accessed June 17, 2025, https://pipelinereview.com/limmatech-vaccinates-first-participants-in-phase-1-study-of-staphylococcus-aureus-vaccine-candidate-lbt-sa7/
50. A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus. | Clinical Research Trial Listing - CenterWatch, accessed June 17, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06719219/a-first-in-human-trial-to-assess-the-safety-and-immunogenicity-of-ltb-sa7-vaccine-against-staphylococcus-aureus
51. Clinical Trials Center Seeks Volunteers for Staphylococcus Aureus Study, accessed June 17, 2025, https://newsroom.tricare.mil/News/Defense-Health-Agency-News/Article/4153314/clinical-trials-center-seeks-volunteers-for-staphylococcus-aureus-study
52. Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial - ClinicalTrials.Veeva, accessed June 17, 2025, https://ctv.veeva.com/study/staphylococcus-aureus-toxoids-phase-1-2-vaccine-trial
53. LTB-SA7 Vaccine - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 17, 2025, https://synapse.patsnap.com/drug/d9244e307d254b67aaa236125201dff3
54. Integrated BioTherapeutics : Quotes, Address, Contact - News-Medical.net, accessed June 17, 2025, https://www.news-medical.net/suppliers/Integrated-BioTherapeutics.aspx
55. Integrated BioTherapeutics: Research-based biotechnology of anti-infective vaccines and drugs, accessed June 17, 2025, http://www.ibtinc-usa.com/index.html
56. Integrated Biotherapeutics LLC - BioCentury Company Profiles - BCIQ, accessed June 17, 2025, https://profiles.biocentury.com/companies/integrated_biotherapeutics_llc
57. About Us - AbVacc, accessed June 17, 2025, https://abvacc.com/about.html
58. NEWS - AbVacc, accessed June 17, 2025, https://abvacc.com/news-details.html
59. Welcome To Abvacc, accessed June 17, 2025, https://www.abvacc.com/
60. Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates - GlobeNewswire, accessed June 17, 2025, https://www.globenewswire.com/news-release/2023/02/01/2599613/0/en/Blue-Water-Vaccines-Announces-Partnership-with-AbVacc-for-Joint-Development-of-Novel-Monkeypox-and-Marburg-Vaccine-Candidates.html
61. NEWS - AbVacc, accessed June 17, 2025, https://abvacc.com/news-details-1.html
62. Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates, accessed June 17, 2025, https://abvacc.com/news-detail-4.html
63. Additional Technologies | LimmaTech Biologics AG, accessed June 17, 2025, https://lmtbio.com/additional-technologies/
64. toxoid vaccines - Page 1 - BioWorld, accessed June 17, 2025, https://www.bioworld.com/keywords/48547-toxoid-vaccines
65. LimmaTech, AbVacc sign licensing agreement for S. aureus vaccine candidate, accessed June 17, 2025, https://www.pharmaceutical-business-review.com/news/limmatech-abvacc-licensing-s-aureus-vaccine/
66. CARB-X funds Immunartes to develop Staphylococcus aureus preventative, accessed June 17, 2025, https://carb-x.org/carb-x-news/carb-x-funds-immunartes-to-develop-staphylococcus-aureus-preventative/
67. CARB-X funds ArrePath to advance novel antibiotic to treat multidrug-resistant infections, accessed June 17, 2025, https://carb-x.org/carb-x-news/carb-x-funds-arrepath-to-advance-novel-antibiotic-to-treat-multidrug-resistant-infections/
68. CARB-X funds Specific Diagnostics to support the development of a rapid accurate test to diagnose life-threatening drug-resistant infections in the blood, accessed June 17, 2025, https://carb-x.org/carb-x-news/carb-x-funds-specific-diagnostics-to-support-the-development-of-a-rapid-accurate-test-to-diagnose-life-threatening-drug-resistant-infections-in-the-blood/
69. Funding Partners - Carb-X, accessed June 17, 2025, https://carb-x.org/partners/funding-partners/
70. CARB-X funds 100th project targeting antibiotic resistance, accessed June 17, 2025, https://carb-x.org/carb-x-news/hips-100th/
71. LimmaTech Biologics - Carb-X, accessed June 17, 2025, https://carb-x.org/gallery/limmatech-biologics-2/